Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.
Dr Mutale discusses common factors contributing to decreased access to cancer clinical trials, how trial enrollment criteria can affect which groups of patients are underrepresented in these trials, and steps that researchers and clinicians can take to increase diversity in clinical trials and mitigate these disparities.
Drs Kovacic, Shaughnessy, Starnes, and Waltz highlight the differences in work culture from their early careers to now, gender-related challenges that persist in medicine today, and advice to incoming medical professionals.
Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.